SORRENTO THERAPEUTICS, INC. Form 8-K (Jan. 21, 2022)

Summary

Current report on Form 8-K for an event dated January 21, 2022, filed by Sorrento Therapeutics, Inc. Under Item 8.01, the report states that on January 21, 2022 the company posted a corporate presentation in the Investors section of the company's website. The presentation provides an overview of the company's Potent Omicron Neutralizing Antibody (nAb) STI-9167 IV and STI-9199 IN. It is filed as Exhibit 99.1, and Henry Ji signed on January 21, 2022.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Cite this document

“SORRENTO THERAPEUTICS, INC. Form 8-K (Jan. 21, 2022).” Original at www.sec.gov. Archived at Pandemic Darlings, https://pandemicdarlings.com/source-documents/sec-srne-8-k-filed2022-01-21-0001104659-22-006282-7fa4a31348/, SHA-256 bcdc1862de9a89f56fd9508b2a4174fcec81afc889b11292022283feede77dcb.

Full text

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event
reported): January 21, 2022

SORRENTO THERAPEUTICS, INC.

(Exact Name of Registrant as Specified
in its Charter)

Delaware | 001-36150 | 33-0344842
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.)

4955 Directors Place

San Diego , CA 92121

(Address of Principal Executive Offices)
(Zip Code)

Registrant’s telephone number,
including area code: ( 858 ) 203-4100

N/A

(Former Name, or Former Address, if Changed
Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities Registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol | Name of each exchange on which registered
Common Stock, $0.0001 par value | SRNE | The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01
Other Information .

On January 21, 2022, Sorrento Therapeutics, Inc.
(the “Company”) posted under the “Investors” section of the Company’s website at www.sorrentotherapeutics.com
a corporate presentation providing an overview of the Company’s Potent Omicron Neutralizing Antibody (nAb) STI-9167 IV and STI-9199
IN (the “Presentation”). A copy of the Presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated
herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1 | Sorrento Therapeutics, Inc. Corporate Presentation Regarding Sorrento Potent Omicron Neutralizing Antibody (nAb) STI-9167 IV and STI-9199 IN.
104 | Cover Page interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

SIGNATURES

Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SORRENTO THERAPEUTICS, INC.
Date: January 21, 2022 | By: | /s/ Henry Ji, Ph.D.
Name: Henry Ji, Ph.D.
Title: Chairman, President and Chief Executive Officer

File and source

File: SEC_SRNE_8-K_filed2022-01-21_0001104659-22-006282.htm
Size: 25,354 bytes
SHA-256: bcdc1862de9a89f56fd9508b2a4174fcec81afc889b11292022283feede77dcb
Our copy: SEC_SRNE_8-K_filed2022-01-21_0001104659-22-006282.htm
Original: www.sec.gov